New dual-tab backing paper developed to facilitate membrane preparation and application

MIAMI, FL, UNITED STATES, November 16, 2026 /EINPresswire.com/ — BioTissue, an eye care company advancing treatments that support ocular surface healing, announced an update to CAM360 AmnioGraft™ (CAM360 AG), its Cryopreserved Amniotic Membrane (CAM) therapy for mild to moderate ocular surface disease. The new dual-tab design was developed to facilitate handling and preparation for eye care professionals (ECPs), while preserving the same CAM360 AG tissue and clinical experience clinicians know and trust.

Introduced in 2024, CAM360 AG featured a ringless, hydrated and shelf-stable design that eliminated the need for refrigeration while delivering treatment experience designed for comfort. Based on real-world feedback, BioTissue developed the new dual-tab design to facilitate greater control and handling during preparation.

“CAM360 AG represented an important step forward in making our CAM therapies accessible to a broader range of patients, including those with mild to moderate ocular surface disease,” said Ted Davis, president and CEO, BioTissue. “Our ongoing partnerships with eye care professionals continue to shape how we advance our products. CAM360 AG Dual Tabs reflects that collaboration, translating insights from everyday clinical practice into meaningful product improvements that support practitioners and their patients.”

Like the original CAM360 AG, the updated design leverages BioTissue’s proprietary cryopreservation technology to preserve the key biological properties of amniotic membrane. CAM technology has been shown to support ocular surface healing through anti-inflammatory, anti-scarring and anti-angiogenic actions1 and may be used across a range of ocular surface conditions, including dry eye disease, superficial punctate keratitis and neurotrophic keratitis.

For more information about BioTissue and CAM360 AG Dual Tabs, visit BioTissue.com.

1.Data on File

About BioTissue, Inc.

BioTissue® is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing across a wide variety of conditions throughout the body, specializing in ocular surface disease, neurotrophic keratitis and nonhealing corneal defects. BioTissue’s portfolio of cryopreserved amniotic membrane products uses its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug (IND) clinical trials as it pursues biologics license applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering health care professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 1.2 million human implants with its products and published 440 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at biotissue.com.

Wendy Boyce
McDougall Communications
+1 5857525805
Visit us on social media:
LinkedIn
Instagram
Facebook

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author